Effect of benzothiazole/piperazine derivatives on intracerebroventricular streptozotocin-induced cognitive deficits

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 834-847

  Özkay, Ümide Demir ^a   Can, Özg̈ur Devrim ^a   Oz̈kay, Yusuf ^a   Oz̈türk, Yusuf ^a  

^a ANADOLU UNIVERSITY   (Turkey)

Author keywords

Acetylcholinesterase; Active avoidance test; Alzheimer's disease; Benzothiazole piperazine; Donepezil; Elevated plus maze test; Morris water maze test; Streptozotocin

Indexed keywords

2 [2 (4 BENZYLPIPERAZIN 1 YL)ACETYLAMINO]BENZOTHIAZOLE; 2 [2 (4 PHENYLPIPERAZIN 1 YL)ACETYLAMINO]BENZOTHIAZOLE; 2 [2 [4 (4 CHLOROBENZYL)PIPERAZIN 1 YL]ACETYLAMINO]BENZOTHIAZOLE; 2 [2 [4 (4 METHOXYBENZYL)PIPERAZIN 1 YL]ACETYLAMINO]BENZOTHIAZOLE; 2 [2 [4 (4 METHYLBENZYL)PIPERAZIN 1 YL]ACETYLAMINO]BENZOTHIAZOLE; ACETYLCHOLINESTERASE; BENZOTHIAZOLE DERIVATIVE; CHOLINESTERASE; DOENZA; DONEPEZIL; FUNCTIONAL GROUP; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; PIPERAZINE DERIVATIVE; SABELUZOLE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; LEARNING; LOCOMOTION; MAZE TEST; MEMORY; MENTAL TEST; NERVOUS SYSTEM PARAMETERS; NONHUMAN; RAT; TREATMENT RESPONSE;

EID: 84867672737     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70878-2     Document Type: Article

References (62)

1. Arce MP, Rodríguez-Franco MI, González-Muńoz GC, Pérez C, López B, Villarroya M, López MG et al.: Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J Med Chem, 2009, 52, 7249-7257.
2. Baluchnejadmojarad T, Roghani M: Effect of naringenin on intracerebroventricular streptozotocin-induced cognitive deficits in rat: a behavioral analysis. Pharmacology, 2006, 78, 193-197. (Pubitemid 44948058)
3. Bassil N, Grossberg GT: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs, 2009, 23, 293-307.
4. Borroni B, Colciaghi F, Pastorino L, Pettenati C, Cottini E, Rozzini L, Monastero R et al.: Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Arch Neurol, 2001, 58, 442-446. (Pubitemid 32217461)
5. Carli M, Balducci C, Millan MJ, Bonalumi P, Samanin RS: 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol, 1999, 128, 1207-1214.
6. Choi MM, Kim EA, Hahn HG, Nam KD, Yang SJ, Choi SY, Kim TU et al.: Protective effect of benzothiazole derivative KHG21834 on amyloid β-induced neurotoxicity in PC12 cells and cortical and mesencephalic neurons. Toxicology, 2007, 239, 156-166. (Pubitemid 47347964)
7. Cumming J, Babu S, Huang Y, Carrol C, Chen X, Favreau L, Greenlee W et al.: Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization. Bioorg Med Chem Lett, 2010, 20, 2837-2842.
8. Demarin V, Zavoreo I, Kes VB, Simundić AM: Biomarkers in Alzheimer's disease. Clin Chem Lab Med, 2011, 49, 773-778.
9. Doody RS: Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol, 1999, 9, 69-77.
10. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 1961, 7, 88-95.
11. Flohr A, Jakob-Roetne R, Norcross RD, Riemer C: Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2A receptor. India Patent, EP1633355B1, 2005.
12. Friedlander AH, Norman DC, Mahler ME, Norman KM, Yagiela JA: Alzheimer's disease: psychopathology, medical management and dental implications. J Am Dent Assoc, 2006, 137, 1240-1251. (Pubitemid 44495442)
13. Geerts H, Nuydens R, De Jong M, Cornelissen F, Nuyens R, Wouters L: Sabeluzole stabilizes the neuronal cytoskeleton. Neurobiol Aging, 1996, 17, 573-581. (Pubitemid 26274257)
14. Girisha HR, Narendra Sharath Chandra JN, Boppana S, Malviya M, Sadashiva CT, Rangappa KS: Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylcholinesterase. Eur J Med Chem, 2009, 44, 4057-4062.
15. Gribkoff VK, Bozik ME: KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6- benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther, 2008, 14, 215-226.
16. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S: Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem, 2007, 101, 757-770. (Pubitemid 46633313)
17. Huang W, Yang G: Microwave-assisted, one-pot syntheses and fungicidal activity of polyfluorinated 2-benzylthiobenzothiazoles. Bioorg Med Chem, 2006, 14, 8280-8285. (Pubitemid 44667557)
18. +-evoked release of somatostatin from rat hippocampal slices. Brain Res, 2001, 892, 111-117.
19. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, Ahmad A et al.: Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol, 2009, 19, 636-647.
20. Kapková P, Stiefl N, Sürig U, Engels B, Baumann K, Holzgrabe U: Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type. Arch Pharm (Weinheim), 2003, 336, 523-540. (Pubitemid 38005047)
21. Kelley BJ, Petersen RC: Alzheimer's disease and mild cognitive impairment. Neurol Clin, 2007, 25, 577-609. (Pubitemid 47058874)
22. Kumar A, Seghal N, Naidu PS, Padi SSV, Goyal R: Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol Rep, 2007, 59, 274-283. (Pubitemid 47299728)
23. Kumar A, Seghal N, Padi SV, Naidu PS: Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur J Pharmacol, 2006, 551, 58-66. (Pubitemid 44648058)
24. Kwon YE, Park JY, No KT, Shin JH, Lee SK, Eun JS, Yang JH et al.: Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1-42 aggregation for Alzheimer's disease therapeutics. Bioorg Med Chem, 2007, 15, 6596-6607. (Pubitemid 47302310)
25. Laras Y, Garino C, Dessolin J, Weck C, Moret V, Rolland A, Kraus JL: New N4-substituted piperazine naphthamide derivatives as BACE-1 inhibitors. J Enzyme Inhib Med Chem, 2009, 24, 181-187.
26. Lecanu L, Tillement L, McCourty A, Rammouz G, Yao W, Greeson J, Papadopoulos V: Dimethyl-carbamic acid 2,3-bis-dimethylcarbamoyloxy-6-(4-ethyl- piperazine-1-carbonyl)-phenyl ester: a novel multi-target therapeutic approach to neuroprotection.Med Chem, 2010, 6, 123-140.
27. Li H, Asberom T, Bara TA, Clader JW, Greenlee WJ, Josien HB, McBriar MD et al.: Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors. Bioorg Med Chem Lett, 2007, 17, 6290-6294. (Pubitemid 47552816)
28. Liu J, Ho W, Lee NT, Carlier PR, Pang Y, Han Y: Bis(7)-tacrine, a novel acetylcholinesterase inhibitor, reverses AF64A-induced deficits in navigational memory in rats. Neurosci Lett, 2000, 282, 165-168. (Pubitemid 30136453)
29. Lleó A, Greenberg SM, Growdon JH: Current pharmacotherapy for Alzheimer's disease. Annu Rev Med, 2006, 57, 513-533. (Pubitemid 43262005)
30. Malgouris C, Bardot F, Daniel M, Pellis F, Rataud J, Uzan A, Blanchard JC et al.: Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci, 1989, 9, 3720-3727. (Pubitemid 20004867)
31. 1 receptor agonistic properties. Behav Brain Res, 1997, 83, 221-224.
32. Matsuoka N, Aigner TG: FK960 [N-(4-acetyl-1-piperazinyl)-p- fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine. J Pharmacol Exp Ther, 1997, 280, 1201-1209. (Pubitemid 27166714)
33. Matsuoka N, Satoh M: FK960, a novel potential antidementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices. Brain Res, 1998, 794, 248-254. (Pubitemid 28300456)
34. Matsuyama S, Nomura T, Nishizaki T: Sustained facilitatory action of FK960 on hippocampal neurotransmission. Brain Res, 2000, 857, 317-320. (Pubitemid 30107823)
35. Maurice T, Privat A: SA4503, a novel cognitive enhancer with sigma1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur J Pharmacol, 1997, 328, 9-18. (Pubitemid 27241388)
36. Miezan Ezoulin JM, Shao BY, Xia Z, Xie Q, Li J, Cui YY, Wang H et al.: Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice. Int J Neuropsychopharmacol, 2009, 12, 1409-1419.
37. Misra S, Tiwari V, Kuhad A, Chopra K: Modulation of nitrergic pathway by sesamol prevents cognitive deficits and associated biochemical alterations in intracerebroventricular streptozotocin administered rats. Eur J Pharmacol, 2011, 659, 177-186.
38. Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, Mendis T: Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clin Neuropharmacol, 1997, 20, 338-345. (Pubitemid 27329735)
39. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods, 1984, 11, 47-60.
40. Mustazza C, Borioni A, Del Giudice MR, Gatta F, Ferretti R, Meneguz A, Volpe MT et al.: Synthesis and cholinesterase activity of phenylcarbamates related to rivastigmine, a therapeutic agent for Alzheimer's disease. Eur J Med Chem, 2002, 37, 91-109. (Pubitemid 34164676)
41. Nagel AA, Liston DR, Jung S, Mahar M, Vincent LA, Chapin D, Chen YL et al.: Design and synthesis of 1-heteroaryl-3-(1-benzyl-4-piperidinyl)propan-1-one derivatives as potent, selective acetylcholinesterase inhibitors. J Med Chem, 1995, 38, 1084-1089.
42. 3H]TCP) binding in human frontal cortex: decreases in Alzheimer-type dementia. J Neurochem, 1990, 54, 526-532.
43. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y: Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol, 2000, 22, 89-95. (Pubitemid 30304435)
44. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P: Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci, 2006, 79, 2209-2216. (Pubitemid 44646475)
45. Paxinos G, Watson C: The rat brain in stereotaxic coordinates, 3rd edn, Academic Press, San Diego, 1997.
46. Perez Velazquez JL: Bicarbonate-dependent depolarizing potentials in pyramidal cells and interneurons during epileptiform activity. Eur J Neurosci, 2003, 18, 1337-1342.
47. Pinton S, da Rocha JT, Zeni G, Nogueira CW: Organoselenium improves memory decline in mice: involvement of acetylcholinesterase activity. Neurosci Lett, 2010, 472, 56-60.
48. Pirondi S, Kuteeva E, Giardino L, Ferraro L, Antonelli T, Bartfai T, Ogren SO et al.: Behavioral and neurochemical studies on brain aging in galanin overexpressing mice. Neuropeptides, 2005, 39, 305-312. (Pubitemid 40804602)
49. Pissarnitski DA, Asberom T, Bara TA, Buevich AV, Clader JW, Greenlee WJ, Guzik HS et al.: 2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors. Bioorg Med Chem Lett, 2007, 17, 57-62. (Pubitemid 44959986)
50. Qu ZQ, Zhou Y, Zeng YS, Li Y, Chung P: Pretreatment with Rhodiola rosea extract reduces cognitive impairment induced by intracerebroventricular streptozotocin in rats: implication of anti-oxidative and neuroprotective effects. Biomed Environ Sci, 2009, 22, 318-326.
51. Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, Gao S et al.: Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement, 2011, 7, 80-93.
52. Román GC, Rogers SJ: Donepezil: a clinical review of current and emerging indications. Expert Opin Pharmacother, 2004, 5, 161-180.
53. Sadashiva CT, Narendra Sharath Chandra JN, Ponnappa KC, Veerabasappa Gowda T, Rangappa KS: Synthesis and efficacy of 1-[bis(4-fluorophenyl)-methyl] piperazine derivatives for acetylcholinesterase inhibition, as a stimulant of central cholinergic neurotransmission in Alzheimer's disease. Bioorg Med Chem Lett, 2006, 16, 3932-3936. (Pubitemid 44425197)
54. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P: Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem, 2006, 96, 1005-1015.
55. Sanchez DJ, Colomina MT, Domingo JL: Effects of vanadium on activity and learning in rats. Physiol Behav, 1998, 63, 345-350. (Pubitemid 28055561)
56. Shigeta M, Homma A: Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev, 2001, 7, 353-368. (Pubitemid 34263871)
57. Sonkusare S, Srinivasan K, Kaul C, Ramarao P: Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci, 2005, 77, 1-14. (Pubitemid 40546372)
58. Sood A, Warren Beach J, Webster SJ, Terry AV, Buccafusco JJ: The effects of JWB1-84-1 on memory-related task performance by amyloid Ab transgenic mice and by young and aged monkeys. Neuropharmacology, 2007, 53, 588-600. (Pubitemid 47513166)
59. Viegas-Junior C, Danuello A, da Silva Bolzani V, Barreiro EJ, Fraga CA: Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem, 2007, 14, 1829-1852. (Pubitemid 47163402)
60. Wilkinson DG: The pharmacology of donepezil: a new treatment of Alzheimer's disease. Expert Opin Pharmacother, 1999, 1, 121-135.
61. Williams M: Progress in Alzheimer's disease drug discovery: an update. Curr Opin Investig Drugs, 2009, 10, 23-34.
62. Xiong Z, Hongmei Z, Lu S, Yu L: Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer's disease. Pharmacol Rep, 2011, 63, 1101-1108.